Prognostic Factors in Gastrointestinal Stromal Tumors: Multicenter Experience of 333 Cases from Turkey

被引:8
作者
Seker, Mesut [1 ]
Sevinc, Alper [2 ]
Yildiz, Ramazan [3 ]
Cihan, Sener [4 ]
Kaplan, Mehmet Ali [5 ]
Gokdurnali, Ayse [6 ]
Dane, Faysal [7 ]
Yaman, Emel [8 ]
Karaca, Halit [9 ]
Colak, Dilsen [10 ]
Uyeturk, Ummugul [6 ]
Bilici, Ahmet [1 ]
Ozdemir, Nuriye Yildirim [4 ]
Kalender, Mehmet Emin [3 ]
Uncu, Dogan [4 ]
Salepci, Taflan [1 ]
Isikdogan, Abdurrahman [5 ]
Benekli, Mustafa [3 ]
Ozkan, Metin [9 ]
Gumus, Mahmut [1 ]
Coskun, Ugur [3 ]
Camci, Celalettin [2 ]
Oksuzoglu, Berna [6 ]
Buyukberber, Suleyman [3 ]
机构
[1] Dr Lutfi Kirdar Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkey
[2] Gaziantep Univ, Dept Med Oncol, Gaziantep Oncol Hosp, Gaziantep, Turkey
[3] Gazi Univ, Dept Med Oncol, Sch Med, Ankara, Turkey
[4] Ankara Res & Training Hosp, Dept Med Oncol, Minist Hlth, Ankara, Turkey
[5] Dicle Univ, Dept Med Oncol, Diyarbakir, Turkey
[6] Dr Abdurrahman Yurtaslan Res & Educ Hosp, Dept Med Oncol, Ankara, Turkey
[7] Marmara Univ, Dept Med Oncol, Sch Med, Istanbul, Turkey
[8] Mersin State Hosp, Dept Med Oncol, Mersin, Turkey
[9] Erciyes Univ, Dept Med Oncol, Sch Med, Kayseri, Turkey
[10] Diskapi Yildirim Beyazit Training & Res Hosp, Dept Med Oncol, Minist Hlth, Ankara, Turkey
关键词
Gastrointestinal stromal tumors; Prognosis; Turkey; TERM-FOLLOW-UP; IMATINIB MESYLATE; DIFFERENTIAL-DIAGNOSIS; DOSE IMATINIB; TRIAL; MANAGEMENT; SURVIVAL;
D O I
10.5754/hge11666
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasm of the gastrointestinal tract. In an attempt to survey the approximate incidence, clinicopathological characteristics, and immunophenotypic features of GISTs in Turkey, we conducted a clinicopathological and immunohistochemical analysis of GISTs. Methodology: Three hundred and thirty-three patients with GIST from nine institutions in Turkey were retrospectively evaluated. Results: Between January 2001 and March 2011, a total of 333 patients with GISTs were included; of these, 204 (61.2%) were male and 129 (38.8%) were female. The median age was 55 years (range; 22402 years). At the median follow-up of 26 months (range; 4-166 months), the 1-, 3- and 5-year OS rates of the 333 patients were 96.9%, 85.8% and 78.5%, respectively. The 5-year DFS rate was 40%. The 5-year OS rate and median OS time for the patients with R-0 resection were significantly higher than for patients with metastatic diseases (79.7 vs. 75.7% and not reached vs. 115 months, respectively, p=0.04). Conclusion: Although our results should be confirmed by prospective studies, we believe that they contribute to the literature because the study included both resectable and metastatic or unresectable GIST patients and multicenter findings from Turkey.
引用
收藏
页码:768 / 775
页数:8
相关论文
共 27 条
[1]   Gastrointestinal stromal tumours (GIST) - 17 years experience from Mid Trent Region (United Kingdom) [J].
Ahmed, I. ;
Welch, N. T. ;
Parsons, S. L. .
EJSO, 2008, 34 (04) :445-449
[2]   Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT [J].
Blanke, Charles D. ;
Demetri, George D. ;
von Mehren, Margaret ;
Heinrich, Michael C. ;
Eisenberg, Burton ;
Fletcher, Jonathan A. ;
Corless, Christopher L. ;
Fletcher, Christopher D. M. ;
Roberts, Peter J. ;
Heinz, Daniela ;
Wehre, Elisabeth ;
Nikolova, Zariana ;
Joensuu, Heikki .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :620-625
[3]   Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease [J].
Cao Hui ;
Zhang Yun ;
Wang Ming ;
Shen Dan-ping ;
Sheng Zhi-yong ;
Ni Xing-zhi ;
Wu Zhi-yong ;
Liu Qiang ;
Shen Yan-ying ;
Song Yan-yan .
CHINESE MEDICAL JOURNAL, 2010, 123 (02) :131-136
[4]   Molecular pathobiology of gastrointestinal stromal sarcomas [J].
Corless, Christopher L. ;
Heinrich, Michael C. .
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE, 2008, 3 :557-586
[5]   Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial [J].
DeMatteo, Ronald P. ;
Ballman, Karla V. ;
Antonescu, Cristina R. ;
Maki, Robert G. ;
Pisters, Peter W. T. ;
Demetri, George D. ;
Blackstein, Martin E. ;
Blanke, Charles D. ;
von Mehren, Margaret ;
Brennan, Murray F. ;
Patel, Shreyaskumar ;
McCarter, Martin D. ;
Polikoff, Jonathan A. ;
Tan, Benjamin R. ;
Owzar, Kouros .
LANCET, 2009, 373 (9669) :1097-1104
[6]   Two hundred gastrointestinal stromal tumors - Recurrence patterns and prognostic factors for survival [J].
DeMatteo, RP ;
Lewis, JJ ;
Leung, D ;
Mudan, SS ;
Woodruff, JM ;
Brennan, MF .
ANNALS OF SURGERY, 2000, 231 (01) :51-58
[7]   Clinical management of gastrointestinal stromal tumors: Before and after STI-571 [J].
DeMatteo, RP ;
Heinrich, MC ;
El-Rifai, WM ;
Demetri, G .
HUMAN PATHOLOGY, 2002, 33 (05) :466-477
[8]   Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].
Demetri, GD ;
von Mehren, M ;
Blanke, CD ;
Van den Abbeele, AD ;
Eisenberg, B ;
Roberts, PJ ;
Heinrich, MC ;
Tuveson, DA ;
Singer, S ;
Janicek, M ;
Fletcher, JA ;
Silverman, SG ;
Silberman, SL ;
Capdeville, R ;
Kiese, B ;
Peng, B ;
Dimitrijevic, S ;
Druker, BJ ;
Corless, C ;
Fletcher, CDM ;
Joensuu, H .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480
[9]   Prognosis of gastrointestinal smooth-muscle (Stromal) tumors - Dependence on anatomic site [J].
Emory, TS ;
Sobin, LH ;
Lukes, L ;
Lee, DH ;
O'Leary, TJ .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1999, 23 (01) :82-87
[10]   Diagnosis of gastrointestinal stromal tumors: A consensus approach [J].
Fletcher, CDM ;
Berman, JJ ;
Corless, C ;
Gorstein, F ;
Lasota, J ;
Longley, BJ ;
Miettinen, M ;
O'Leary, TJ ;
Remotti, H ;
Rubin, BP ;
Shmookler, B ;
Sobin, LH ;
Weiss, SW .
HUMAN PATHOLOGY, 2002, 33 (05) :459-465